Login / Signup

Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study.

Joachim SieperRobert LandewéMarina MagreyJaclyn K AndersonSheng ZhongXin WangApinya Lertratanakul
Published in: RMD open (2019)
In ABILITY-3, consistent and strong baseline predictors of remission included younger age, male sex, HLA-B27 positivity and higher SPARCC MRI sacroiliac joint score among patients with active nr-axSpA receiving adalimumab therapy, similar to previous findings in ankylosing spondylitis.
Keyphrases